The effect of montelukast therapy on messenger ribonucleic acid (mRNA) profile of matrix metalloproteinases and their inhibitors in the sputum of patients with asthma

Trial Profile

The effect of montelukast therapy on messenger ribonucleic acid (mRNA) profile of matrix metalloproteinases and their inhibitors in the sputum of patients with asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Sep 2009

At a glance

  • Drugs Montelukast (Primary)
  • Indications Asthma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 02 Sep 2009 Status changed from unconfirmed to completed as reported by ISRCTN: Current Controlled Trials.
    • 24 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top